THN102

ID: thn102

Aliases: modafinil plus low-dose flecainide

Type: combination

Route/form: oral or route depends on studied product

Status: investigational

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, non-human/mechanistic

Source types: human_rct, preclinical

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• dopamine transporter inhibition
• astroglial connexin inhibition

Optimization domains

• wakefulness
• cognition
• narcolepsy
• sleep deprivation

Research basis

• Human sleep-deprivation study found better vigilance/cognitive signals than modafinil alone at tested combinations.
• Mechanistic package ties glial connexins to modafinil response modulation.

Limits, risks, and missing evidence

• Flecainide is an antiarrhythmic with serious cardiac-conduction implications at therapeutic use.
• Combination is not interchangeable with casual modafinil stacking.

Risk flags

• cardiac conduction
• investigational
• medical supervision

Linked papers, labels, and reviews

1. THN102 during 40-hour total sleep deprivation in healthy subjects
   human_rct / pubmed_thn102_2019
   Modafinil plus low-dose flecainide combination.
2. Cortico-amygdala-striatal activation by modafinil/flecainide combination
   preclinical / pubmed_modafinil_flecainide_2018
   Rodent FDG-PET support for THN102 mechanism.